Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

on behalf of the LOTUS investigators

Research output: Contribution to journalArticlepeer-review

225 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences